Observational prospective study (n=8 actual enrolled) assessing EEG, pupillometry and belief-updating before and after clinically prescribed esketamine (intranasal 28–84 mg) in people with MDD.
Monocentric, prospective observational study assessing immediate and longer-term (≈8 weeks) effects of clinically prescribed esketamine nasal spray on brain network activity and belief updating in individuals with major depressive disorder.
EEG and pupillometry are recorded before and after esketamine administration in two experimental sessions; a Belief Updating Task measures cognitive changes related to optimistic update bias.
Analyses will relate neurophysiological signatures to changes in belief updating and depressive symptomatology over the treatment period.
Participants with treatment-resistant MDD receiving clinically prescribed esketamine nasal spray; EEG, pupillometry and belief-updating measured before and after dosing in two sessions.
Intranasal spray (Spravato); doses 28–84 mg administered per clinical care; observational study.